Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 8/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22579095 | 0.81 | ADORA2A (0.51) | MAPKAPK2ADORA2AADORA1ATR | |
| SCHEMBL22551940 | 0.76 | MAPKAPK2 (0.42) | MAPKAPK2ATR | |
| SCHEMBL22579094 | 0.75 | KDM4E (0.38) | ADORA2AADORA1 | |
| SCHEMBL22579103 | 0.73 | ADORA2A (0.45) | ADORA2AADORA1LMNA | |
| SCHEMBL13680609 | 0.71 | HDAC1 (0.47) | ATRLMNA | |
| SCHEMBL21722802 | 0.70 | KDM4E (0.36) | ADORA2AADORA1 | |
| SCHEMBL3028012 | 0.70 | PKM (0.45) | — | |
| SCHEMBL11927607 | 0.67 | MAPKAPK2 (0.57) | MAPKAPK2 | |
| SCHEMBL24423243 | 0.65 | STK17B (0.50) | MAPKAPK2ATRLMNA | |
| SCHEMBL22552136 | 0.65 | MAPKAPK2 (0.43) | MAPKAPK2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | MAPKAPK2 1351/4885ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.